

Akronym	Bezeichnung	Phase	Indikation	Beschreibung	Rekrutierung
IPF STUDIEN					
ISABELA 1 &2	GLPG1690-CL-304	III	Idiopathische Lungenfibrose	A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.	Aktiv
Nitto-Denko	ND-L02s-0201-005	II	Idiopathische Lungenfibrose	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	Aktiv
Novartis	CVAY736X2207	II	Idiopathische Lungenfibrose	A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis	Aktiv
ZEPHYRUS	FibroGen FGCL-3019-091	III	Idiopathische Lungenfibrose	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	In Vorbereitung
Respivant	RVT1601-CC-04	IIb	Idiopathische Lungenfibrose Behandlung des Hustens	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Aktiv

Nicht-IPF STUDIEN					
INBUILD-ON	1199.248	III	PF-ILD	An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)	Rekrutierung beendet
Alveolar Proteinose STUDIEN					
IMPALA	IMPALA MOL PAPA 202 Extension	III	Alveolar Proteinose	An open-label, non-controlled, multicentre trial of inhaled Molgramotism in autoimmune pulmonary alveolar proteinosis patients	Rekrutierung beendet
Sarkoidose STUDIEN					
Novartis	CCMK389X2201	II	Sarkoidose	A subject and investigator blinded, randomized, placebocontrolled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis.	In Vorbereitung